Review
doi: 10.2165/11584530-000000000-00000.
Tremelimumab
- PMID: 20698721
- PMCID: PMC3586090
- DOI: 10.2165/11584530-000000000-00000
Item in Clipboard
Review
Tremelimumab
Drugs R D.
2010.
Abstract
Tremelimumab (CP 675206; CP-675; CP-675,206; CP-675206; Ticilimumab) is a fully human IgG2 anitbody, which is directed against human cytotoxic T lymphocyte-associated antigen 4 (CTLA4). It is being developed by Pfizer for the treatment of various cancers. It is currently in worldwide phase III development for malignant melanoma, phase II development for colorectal cancer, gastrointestinal cancer, gynecological cancer, and non-small cell lung cancer in the US and other countries, and is also being investigated for prostate, breast, and pancreatic cancer in various countries. This review discusses the key development milestones and therapeutic trials of this drug.
Figures
Features and properties
History
Forecasts
Similar articles
-
Tremelimumab, a fully human monoclonal IgG2 antibody against CTLA4 for the potential treatment of cancer.Curr Opin Mol Ther. 2007 Oct;9(5):505-14. Curr Opin Mol Ther. 2007. PMID: 17932815 Review.
-
Novel therapies targeting the immune system: CTLA4 blockade with tremelimumab (CP-675,206), a fully human monoclonal antibody.Expert Opin Investig Drugs. 2008 Mar;17(3):371-85. doi: 10.1517/13543784.17.3.371. Expert Opin Investig Drugs. 2008. PMID: 18321236 Review.
-
Tremelimumab (CP-675,206): a fully human anticytotoxic T lymphocyte-associated antigen 4 monoclonal antibody for treatment of patients with advanced cancers.Expert Opin Biol Ther. 2008 Oct;8(10):1583-93. doi: 10.1517/14712598.8.10.1583. Expert Opin Biol Ther. 2008. PMID: 18774925
-
Ipilimumab.Drugs R D. 2010;10(2):97-110. doi: 10.2165/11584510-000000000-00000. Drugs R D. 2010. PMID: 20698719 Free PMC article. Review.
-
Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with tremelimumab (CP-675,206).Oncologist. 2008;13 Suppl 4:10-5. doi: 10.1634/theoncologist.13-S4-10. Oncologist. 2008. PMID: 19001146 Review.
Cited by
-
A functional antibody cross-reactive to both human and murine cytotoxic T-lymphocyte-associated protein 4 via binding to an N-glycosylation epitope.MAbs. 2020 Jan-Dec;12(1):1725365. doi: 10.1080/19420862.2020.1725365. MAbs. 2020. PMID: 32054416 Free PMC article.
-
In or out of control: Modulating regulatory T cell homeostasis and function with immune checkpoint pathways.Front Immunol. 2022 Dec 15;13:1033705. doi: 10.3389/fimmu.2022.1033705. eCollection 2022. Front Immunol. 2022. PMID: 36591244 Free PMC article.
-
Therapeutic Targets of Monoclonal Antibodies Used in the Treatment of Cancer: Current and Emerging.Biomedicines. 2023 Jul 24;11(7):2086. doi: 10.3390/biomedicines11072086. Biomedicines. 2023. PMID: 37509725 Free PMC article. Review.
-
Combination Immunotherapy Approaches for Pancreatic Cancer Treatment.Can J Gastroenterol Hepatol. 2018 Mar 7;2018:6240467. doi: 10.1155/2018/6240467. eCollection 2018. Can J Gastroenterol Hepatol. 2018. PMID: 29707526 Free PMC article. Review.
-
A perspective of immunotherapy for acute myeloid leukemia: Current advances and challenges.Front Pharmacol. 2023 Apr 19;14:1151032. doi: 10.3389/fphar.2023.1151032. eCollection 2023. Front Pharmacol. 2023. PMID: 37153761 Free PMC article. Review.
References
-
- Pfizer and Debiopharm collaborate to co-develop investigational compound tremelimumab (CP-675,206) in advanced melanoma. 2010.
-
- Medarex Announces Major Antibody Strategic Alliance with Pfizer. 2004.
-
- Chung KY, Gore I, Fong L, et al. A phase II study of the anti-CTLA4 monoclonal antibody, CP-675,206, in patients with refractory metastatic adenocarcinoma of the colon or rectum. J Clin Oncol. 2007;25:126.
-
- Pfizer Announces Discontinuation of Phase III Clinical Trial for Patients with Advanced Melanoma. 2008.
-
- Pfizer Fourth-Quarter and Full-Year 2005 Financial Results Reflect Operating and Financial Strength. 2006.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous